Mainpointe Drug Patent Portfolio
Mainpointe owns 1 orange book drug protected by 4 US patents Given below is the list of Mainpointe's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9066942 | Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer | 03 Jan, 2032 | Active |
| US9107921 | Oral dosage forms for oxygen containing active agents and oxyl-containing polymers | 03 Jan, 2032 | Active |
| US6248363 | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions | 23 Nov, 2019 | Expired |
| US6383471 | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents | 06 Apr, 2019 | Expired |
Latest Legal Activities on Mainpointe's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Mainpointe.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 08 Feb, 2023 | US9107921 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 01 Dec, 2022 | US9066942 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 02 Jan, 2019 | US9066942 |
| Surcharge for late Payment, Small Entity | 02 Jan, 2019 | US9066942 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 30 Nov, 2018 | US9107921 |
|
Application ready for PDX access by participating foreign offices
Critical
| 31 Aug, 2015 | US9107921 |
|
Application ready for PDX access by participating foreign offices
Critical
| 31 Aug, 2015 | US9066942 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 18 Aug, 2015 | US9107921 |
|
Recordation of Patent Grant Mailed
Critical
| 18 Aug, 2015 | US9107921 |
|
Email Notification
Critical
| 30 Jul, 2015 | US9107921 |
|
Issue Notification Mailed
Critical
| 29 Jul, 2015 | US9107921 |
|
Application Is Considered Ready for Issue
Critical
| 21 Jul, 2015 | US9107921 |
| Dispatch to FDC | 21 Jul, 2015 | US9107921 |
|
Issue Fee Payment Verified
Critical
| 10 Jul, 2015 | US9107921 |
| Supplemental Papers - Oath or Declaration | 10 Jul, 2015 | US9107921 |
Mainpointe's Family Patents
Mainpointe Drug List
Given below is the complete list of Mainpointe's drugs and the patents protecting them.
1. Tuxarin Er
Tuxarin Er is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9066942 | Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer |
03 Jan, 2032
(6 years from now)
| Active |
| US9107921 | Oral dosage forms for oxygen containing active agents and oxyl-containing polymers |
03 Jan, 2032
(6 years from now)
| Active |
| US6248363 | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
23 Nov, 2019
(5 years ago)
| Expired |
| US6383471 | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
06 Apr, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tuxarin Er's drug page